Positron emission tomography in the management of lymphomas

M J O'Doherty; E A Macdonald; S F Barrington; N G Mikhaeel; S Schey

doi:10.1053/clon.2002.0118

Positron emission tomography in the management of lymphomas

M J O'Doherty, E A Macdonald, S F Barrington, N G Mikhaeel, S Schey

Research output: Contribution to journal › Literature review › peer-review

26 Citations (Scopus)

Abstract

Positron emission tomography is a functional imaging modality that capitalizes on biochemical changes within tumour cells to localize these changes within the body. As a functional imaging tool, unlike an anatomical imaging tool such as CT, it does not require enlargement of lymph nodes affected by disease but does require sufficient numbers of tumour cells to be present with altered biochemical function to visualize these disease sites. These changes are most commonly monitored using a glucose mimic fluorodeoxyglucose which is not only taken up into tumour cells but is trapped within these cells owing to alterations of the hexokinase and dephosphorylase enzymes. This review examines the current role of FDG PET imaging in patients with Hodgkins and Non-Hodgkins lymphoma and also speculates on future roles for this imaging modality.

Original language	English
Pages (from-to)	415 - 426
Number of pages	12
Journal	Clinical Oncology
Volume	14
Issue number	5
DOIs	https://doi.org/10.1053/clon.2002.0118
Publication status	Published - Oct 2002

Access to Document

10.1053/clon.2002.0118

Cite this

@article{b9bf69f18cf642388521c43455289f89,

title = "Positron emission tomography in the management of lymphomas",

abstract = "Positron emission tomography is a functional imaging modality that capitalizes on biochemical changes within tumour cells to localize these changes within the body. As a functional imaging tool, unlike an anatomical imaging tool such as CT, it does not require enlargement of lymph nodes affected by disease but does require sufficient numbers of tumour cells to be present with altered biochemical function to visualize these disease sites. These changes are most commonly monitored using a glucose mimic fluorodeoxyglucose which is not only taken up into tumour cells but is trapped within these cells owing to alterations of the hexokinase and dephosphorylase enzymes. This review examines the current role of FDG PET imaging in patients with Hodgkins and Non-Hodgkins lymphoma and also speculates on future roles for this imaging modality.",

author = "O'Doherty, {M J} and Macdonald, {E A} and Barrington, {S F} and Mikhaeel, {N G} and S Schey",

year = "2002",

month = oct,

doi = "10.1053/clon.2002.0118",

language = "English",

volume = "14",

pages = "415 -- 426",

journal = "Clinical Oncology",

issn = "1433-2981",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Positron emission tomography in the management of lymphomas

AU - O'Doherty, M J

AU - Macdonald, E A

AU - Barrington, S F

AU - Mikhaeel, N G

AU - Schey, S

PY - 2002/10

Y1 - 2002/10

N2 - Positron emission tomography is a functional imaging modality that capitalizes on biochemical changes within tumour cells to localize these changes within the body. As a functional imaging tool, unlike an anatomical imaging tool such as CT, it does not require enlargement of lymph nodes affected by disease but does require sufficient numbers of tumour cells to be present with altered biochemical function to visualize these disease sites. These changes are most commonly monitored using a glucose mimic fluorodeoxyglucose which is not only taken up into tumour cells but is trapped within these cells owing to alterations of the hexokinase and dephosphorylase enzymes. This review examines the current role of FDG PET imaging in patients with Hodgkins and Non-Hodgkins lymphoma and also speculates on future roles for this imaging modality.

AB - Positron emission tomography is a functional imaging modality that capitalizes on biochemical changes within tumour cells to localize these changes within the body. As a functional imaging tool, unlike an anatomical imaging tool such as CT, it does not require enlargement of lymph nodes affected by disease but does require sufficient numbers of tumour cells to be present with altered biochemical function to visualize these disease sites. These changes are most commonly monitored using a glucose mimic fluorodeoxyglucose which is not only taken up into tumour cells but is trapped within these cells owing to alterations of the hexokinase and dephosphorylase enzymes. This review examines the current role of FDG PET imaging in patients with Hodgkins and Non-Hodgkins lymphoma and also speculates on future roles for this imaging modality.

U2 - 10.1053/clon.2002.0118

DO - 10.1053/clon.2002.0118

M3 - Literature review

SN - 1433-2981

VL - 14

SP - 415

EP - 426

JO - Clinical Oncology

JF - Clinical Oncology

IS - 5

ER -

Positron emission tomography in the management of lymphomas

Abstract

Access to Document

Fingerprint

Cite this